Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.72 |
| ▸ | CA6 | P23280 | 5/20 | 0.72 |
| ▸ | CA7 | P43166 | 5/20 | 0.72 |
| ▸ | CA9 | Q16790 | 5/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.72 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.72 |
| ▸ | CA2 | P00918 | 4/20 | 0.72 |
| ▸ | CA4 | P22748 | 4/20 | 0.72 |
| ▸ | CA5A | P35218 | 4/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.72 |
| ▸ | CA3 | P07451 | 3/20 | 0.72 |
| ▸ | F13A1 | P00488 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | THPO | P40225 | 2/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | MTOR | P42345 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690237 | 0.88 | — | — | |
| SCHEMBL323273 | 0.87 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL448382 | 0.87 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL732232 | 0.87 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL2012007 | 0.87 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL322518 | 0.87 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL138047 | 0.87 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL16295924 | 0.84 | CA12 (0.87) | CA12CA6CA7CA9CA14 | |
| SCHEMBL16281062 | 0.84 | CA12 (0.87) | CA12CA6CA7CA9CA14 | |
| SCHEMBL5078139 | 0.84 | CA12 (0.87) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050233948-A1 | Drug complex for treatment of metastatic prostate cancer | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2005-10-20 | — | — | US | claimed |
| US-20030035804-A1 | Drug complex for treatment of metastatic prostate cancer | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2003-02-20 | — | — | US | claimed |
| US-6368598-B1 | ADMINISTERING COMPLEX OF POLYAMINE CARRIER, DRUG AND CONNECTOR | JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. | 2002-04-09 | — | — | US | claimed |
| WO-2000001419-A1 | DRUG COMPLEX FOR TREATMENT OF METASTATIC PROSTATE CANCER | JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. (US) | 2000-01-13 | — | — | WO | claimed |
| US-20050233948-A1 | Drug complex for treatment of metastatic prostate cancer | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2005-10-20 | — | — | US | disclosed |
| US-20030035804-A1 | Drug complex for treatment of metastatic prostate cancer | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6368598-B1 | ADMINISTERING COMPLEX OF POLYAMINE CARRIER, DRUG AND CONNECTOR | JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2000001419-A1 | DRUG COMPLEX FOR TREATMENT OF METASTATIC PROSTATE CANCER | JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233948-A1 | Drug complex for treatment of metastatic prostate cancer | KLK3, ACP3, FOLH1 | CA12 141/4885CA6 283/4885CA7 572/4885 |
| US-20030035804-A1 | Drug complex for treatment of metastatic prostate cancer | KLK3, ACP3, FOLH1 | CA12 141/4885CA6 283/4885CA7 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.